Bio Products Laboratory Ltd (BPL), a leading manufacturer of plasma-derived protein therapies, joins the global bleeding disorders community in recognition of World Hemophilia Day (WHD). Observed annually on 17 April, WHD honours Frank Schnabel’s birthday, a person who suffered from severe hemophilia, and subsequently established the World Federation of Hemophilia (WFH).
Organised by the WFH, this year’s theme is “Access for All: Partnership. Policy. Progress. Engaging your government, integrating inherited bleeding disorders into national policy”. The campaign promotes the importance of taking coordinated and concerted actions to bring hemophilia and other inherited bleeding disorders to the attention of policymakers with the aim of increasing sustainable and equitable access to care and treatment.
According to the latest data from WFH, hemophilia (including rare bleeding disorders), affects about 393,658 people globally. Usually, a person inherits hemophilia, but in rare cases, it can be developed later in life. People with bleeding disorders can experience symptoms such as bruising, nosebleeds, joint pain and swelling, heavy menstrual bleeding in women, as well as life threatening bleeds in the brain or stomach. Symptoms are caused by a deficiency in one or more of the clotting factors that controls bleeding.
BPL manufactures its plasma-derived therapies by processing plasma collected from its donor communities and strives to develop treatments which make a different to the lives of people living with coagulation factor deficiencies like hemophilia.
As part of its ongoing commitment throughout the year and in support of the Access for All campaign, BPL will attend the WFH 2022 World Congress, which will cover the latest medical and multidisciplinary developments in the field. The WFH and the Canadian Hemophilia Society (CHS) will welcome the global bleeding disorders community in Montreal, Canada, and virtually via the WFH 2022 Virtual Congress website.
Bob Rossilli, Chief Commercial Officer, Global Business, said, “We join World Hemophilia Day in raising awareness about hemophilia and endeavouring to increase access to crucial treatments.
Central to our mission here at BPL is enabling people with rare bleeding disorders to live normal, healthy lives. We are proud to apply our expertise, experience, and resources in the development and improvement of new and existing treatments, helping to sustain care and secure access to treatment for patients with rare bleeding disorders.
We look forward to sharing more on this during the WFH 2022 World Congress”.
To find out more about World Haemophilia Day 2022, please visit:
Donna Mitchell, BPL Communications Manager
About Bio Products Laboratory (BPL)
Recognising the importance of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom, with US offices in Durham, NC, and plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com.
BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 28 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL’s plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners.